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Gel permeation chromatography (GPC). This was performed in an Alliance 2695 separation module (Waters) equipped with a HELEOS Multi Angle Laser Light Scattering detector and an Optilab rEX differential refractometer (Wyatt Technology Corporation). Each GPC sample was prepared at 3-5 mg·mL −1 in 0.1 M citric acid (pH 2.7) for GPC analysis. Its data were analyzed with Astra 5.3.14 software (Wyatt Technology Corporation) to extract the values of weightaverage molecular weight (M w ), number-average molecular weight (M n ) and polydispersity index (PDI = M w ·M n −1 ). Unmodified G5 PAMAM dendrimer has a molecular weight of M w = 26,600 g·mol -1 with a PDI value of 1.010.
Dynamic Light Scattering (DLS) and Zeta Potential (ZP). DLS and ZP measurements were
performed on a Zetasizer Nano-ZS (Malvern Instruments Ltd.) using a same dendrimer sample prepared in 1 mM HEPES (pH 7) as described previously. 4 Errors reported for the size and ZP measurements refer to standard deviation values.
Surface plasmon resonance (SPR) spectroscopy. SPR experiments were carried out in a Biacore® X instrument (Pharmacia Biosensor AB). A CM5 sensor chip (Pharmacia Biosensor) immobilized with lipopolysaccharides (LPS) was prepared as described previously. 5 This immobilization was achieved by the injection of an amine-modified LPS solution (5 mg·mL −1 , pH 9; 35 L) to flow cell 1 (Fc1) preactivated with EDC/NHS (1:1 mixture of 0.4 M EDC and 0.1 M NHS; 70 L). A reference cell was prepared by the treatment of flow cell 2 in the same manner as above but without the injection of the LPS solution.
SPR sensorgrams were acquired by the injection (50 L) of analyte solutions, each prepared in HBS-EP buffer, at a flow rate of 30 L/min. The chip surface was regenerated by treatment with 10 L of a 10 mM glycine-HCl (pH 2.5) buffer at the end of each dissociation phase (t ≥ 600 s).
Prior to kinetic analysis, each sensorgram in Fc1 (RU 1 ) was corrected for the contribution of non-specific adsorption by the subtraction of the reference sensorgram in Fc2 (RU 2 ): RU (corrected) = RU 1 -RU 2 . Global fitting analysis was performed for each corrected sensorgram to extract dissociation (off) rate constant k off and association (on) rate constant k on using a Langmuir binding model. 6 Dissociation constant (K D ) was calculated by using two kinetic parametersassociation (on) rate constant k on and dissociation (off) rate constant k off : K D = (k off ÷ k on ). Each K D value refers to a mean of four or more independent measurements (n ≥ 4).
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II. Synthesis of 3 G5(ONB-Cipro) m and 4 G5(PMB) n (ONB-Cipro) m
II.1. Synthesis of 2 ONB-Cipro. Compound S2:
To a solution of S1 ONB-OH (50 mg, 0.125 mmol) 3 
III. Light-controlled Release Kinetics
Kinetics of drug release controlled by UV light was performed with a Spectroline® UV lamp device (XX-15A; maximal emission intensity at 365 nm). 3, 7, 8 Typically, a solution of 2 ONB-Cipro (0.13 mM in methanol) or 3-4 G5(PMB)(ONB-Dox) (0.032 mM in water) was exposed to S9 a light source at the distance of ~5 cm. A series of aliquots were taken as a function of exposure time, and analyzed by UPLC and UV-vis spectrometry to determine the rate of ciprofloxacin release from photocaged ciprofloxacin.
IV. Confocal Microscopy
E. Coli (XL-1) was grown in LB broth overnight in a 37°C shaker. Cells were washed with fresh LB, and 5 × 10 7 CFU were incubated with 5 M of the FITC-labeled control dendrimer, "FITC-(Ac)G5" or drug conjugate, "FITC-G5(PMB) 1.1 (ONB-Cipro) 8 Figure S8 . Effects of dendrimer conjugates on the hemolysis of red blood cells (RBCs). Conjugates and compounds tested: G5(EA), G5(GA), 3 G5(EA) 40 (ONB-Cipro) 8.5 , 4 G5(PMB) 1.1 (ONB-Cipro) 8.5 , 2 ONB-Cipro and dextran (a negative control). Unit for doses = M. Each data point refers to a mean value (±SD). Inset is an expanded plot for clarity.
Assay protocol: Sheep RBCs (2%, Rockland Immunochemicals, PA) in PBS (pH 7.4) were treated with each conjugate at various doses for 30 min, 1 h and 24 h, and their hemolysis (%) was determined by the established assay protocol reported in literature. 12 Typically, after incubation, the treated cells were centrifuged, and the supernatant was measured for its absorption at 550 nm for the quantification of hemoglobin which is released following the membrane rupture. Hemolysis values (%) are reported relative to Triton X-100 (1% v/v) as a positive control which is set as 100%. 
